FinancialContent is the trusted provider of stock market information to the media industry.
More NewsRead More
Advaxis Announces Initiation of Phase 1/2 Trial of ADXS-HPV in Head and Neck Cancer Conducted by Icahn School of Medicine at Mount Sinai
November 20, 2013
Advaxis Reports Final 18-Month Survival Data for ADXS-HPV in Patients with Recurrent Cervical Cancer at the 2013 Society for Immunotherapy of Cancer Annual Meeting
November 08, 2013
QualityStocks News - Advaxis, Inc. (ADXS) Receives Orphan Drug Designation for ADXS-HPV for Treating HPV-Associated Head and Neck Cancer
November 06, 2013
BRIEF-Advaxis up 22 pct premarket; signs license deal with Global BioPharma to develop ADXS-HPV in Asia
Today 8:01 EST
Advaxis’ ADXS-HPV Granted Orphan Drug Designation for Treatment of HPV-Associated Head and Neck Cancer
November 05, 2013
Advaxis Signs License Agreement for Development and Commercialization of ADXS-HPV in Asia
Today 7:32 EST
Advaxis Appoints Gregory T. Mayes as Chief Operating Officer
October 28, 2013
Advaxis Canine Cancer Vaccine Featured on ABC News
November 22, 2013
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here